Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has received two significant patent approvals from the United States Patent and Trademark Office (USPTO) for its ImmCelz cell therapy platform, expanding intellectual property protection for treatments targeting heart failure and Type 1 diabetes. The clinical-stage biotechnology company announced the Notice of Allowance approvals in July 2025, with both patents remaining in effect until at least 2040.
Heart Failure Treatment Patent
The first patent, titled "Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells," provides broad claims for treating patients at risk of developing or already experiencing heart failure. The patent specifically addresses post-infarct pathological remodeling, a condition that can develop after heart attacks and lead to reduced heart function and potential heart failure.
According to the company, the total treatable heart failure population in the United States exceeds five million patients. Additionally, over six million patients with chronic chest pain (refractory angina) despite maximal medical and surgical therapy may benefit from the ImmCelz product. The treatment is delivered through an ultra-minimally invasive outpatient procedure.
Type 1 Diabetes Immunotherapy Patent
The second patent, "Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity," enables a broad cell-based immunotherapy approach for Type 1 diabetes using the ImmCelz product. This includes supercharged T regulatory cells using the company's proprietary cell-free solutions, with validation conducted using cells from patients with Type 1 diabetes.
Type 1 diabetes is an autoimmune disease where the body's immune system attacks and destroys insulin-producing beta cells in the pancreas. The destruction of these cells leads to insulin deficiency and diabetes development, as beta cells produce insulin essential for moving glucose from blood into cells for energy.
"We believe that the use of ImmCelz to prevent and/or treat Type 1 Diabetes is regenerative immunotherapy in its truest form," said Timothy Warbington, CEO of Creative Medical. "The treatment of Type 1 Diabetes remains a primary focus for our Company, as evidenced by our ongoing CREATE-1 clinical trial."
ImmCelz Platform Technology
The ImmCelz platform utilizes a patient's own extracted immune cells that are "reprogrammed/supercharged" by culturing them outside the patient's body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. Creative Medical believes this process endows the immune cells with regenerative properties on top of their original innate functions, providing the ability to treat multiple indications.
Strategic Implications
"This Notice of Allowance further strengthens our already robust intellectual property portfolio and reflects the potential of our cell-based technology to develop therapies that support the reprogramming, regrowth, and repair of the body across multiple indications," Warbington stated regarding the heart failure patent. "This latest allowance adds further value to our franchise and will help to support the continuing growth and evolution of our regenerative medicine platform."
The patent approvals represent significant milestones for Creative Medical Technology Holdings as it advances its regenerative medicine platform across multiple therapeutic areas, including pain management, neurology, and urology. The company continues to leverage cutting-edge cell therapy technologies to develop transformative treatments aimed at improving patient outcomes.
